Search Clinical Trials
Before medications are approved by the U.S. Food and Drug Administration (FDA) or before certain therapy methods are widely accepted as effective, they are tested on people who volunteer to participate in a clinical trial.
Organizations across the country are looking for people like you to take part in their research studies. The list of studies below have been selected from ClinicalTrials.gov based on their inclusion of one or more of the following terms: anxiety disorders, depression, OCD, PTSD, and bipolar disorder.
The Anxiety and Depression Association of America (ADAA) is supportive of research that is conducted through clinical trials. Participating in research can potentially help change the mental health outcomes for you and others who suffer anxiety, depression, and related disorders. You may learn about new interventions/treatments that are being considered.
Read this ADAA blog about things to know and questions to ask before committing to a clinical trial.
This website page is brought to you in partnership with ResearchMatch.
Sponsor Condition of Interest |
---|
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants...
Janssen Research & Development, LLC
Depressive Disorder, Major
Anhedonia
The purpose of this study is to assess how well aticaprant works compared to placebo when
given in addition to antidepressant therapy (selective serotonin reuptake inhibitor
[SSRI] or serotonin-norepinephrine reuptake inhibitor [SNRI]) in preventing return of
depression symptoms in participants with... expand
The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective serotonin reuptake inhibitor [SSRI] or serotonin-norepinephrine reuptake inhibitor [SNRI]) in preventing return of depression symptoms in participants with major depressive disorder who experience a loss of interest and pleasure and who achieve a stable response after treatment with adjunctive aticaprant. Type: Interventional Start Date: Sep 2024 |
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Autobahn Therapeutics, Inc.
Major Depressive Disorder
The goal of this clinical trial is to learn if ABX-002 added to an existing
antidepressant treatment will benefit depression symptoms in adults with moderate to
severe major depressive disorder who have had an inadequate response to their
antidepressant.
This is a double-blind, placebo-controlled,... expand
The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant. This is a double-blind, placebo-controlled, 2-arm, parallel-group, Phase 2 study, randomized 1:1 (ABX-002: placebo). The study will include the following stages: 1. Screening, Eligibility evaluation and 1:1 Randomization to ABX-002 vs. Placebo control (Baseline - Day 1); approximately 35 days 2. 42-day Treatment Period 3. 2-week post dose Safety Follow-up Period Type: Interventional Start Date: Sep 2024 |
Cognitive Control Training for Extinction in PTSD
VA Office of Research and Development
Post-Traumatic Stress Disorders
Stress Disorders, Traumatic
Post Traumatic Stress Disorder
PTSD
Trauma and Stressor Related Disorders
The proposed study will test whether a working memory training (WMT) program improves
fear extinction learning and its underlying neural circuitry in Veterans with
posttraumatic stress disorder (PTSD). WMT is designed to improves the ability to maintain
task-relevant information in mind. The project... expand
The proposed study will test whether a working memory training (WMT) program improves fear extinction learning and its underlying neural circuitry in Veterans with posttraumatic stress disorder (PTSD). WMT is designed to improves the ability to maintain task-relevant information in mind. The project will further validate the relationship between working memory and fear extinction using novel computational and multivariate analyses that link to specific PTSD symptoms. If WMT can enhance fear extinction learning, then WMT may be a powerful adjunctive treatment that can enhance exposure therapy outcomes or be leveraged as a stand-alone treatment. This project supports the Department of Veteran Affairs mission of developing viable targets of treatment for Veterans with PTSD. Type: Interventional Start Date: Oct 2024 |
A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder...
Janssen Research & Development, LLC
Depressive Disorder, Major
Anhedonia
The purpose of this study is to evaluate how well aticaprant works as compared with
placebo when given along with an antidepressant therapy in improving the depressive
symptoms in adult participants with major depressive disorder (MDD) with moderate to
severe anhedonia (ANH+) who have not responded... expand
The purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improving the depressive symptoms in adult participants with major depressive disorder (MDD) with moderate to severe anhedonia (ANH+) who have not responded well to current antidepressant therapy with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI or SNRI). Type: Interventional Start Date: Jun 2024 |
RE104 Safety and Efficacy Study in Postpartum Depression
Reunion Neuroscience Inc
Postpartum Depression
The purpose of this study is to determine if treatment with a single dose of RE104 for
Injection reduces depressive symptoms in participants with moderate-to-severe postpartum
depression (PPD) as compared to active-placebo. expand
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-placebo. Type: Interventional Start Date: Jun 2024 |
Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants...
AbbVie
Bipolar I Disorder
Bipolar I disorder (BP-I) is a common, chronic, and disabling mental illness with
significant morbidity and mortality defined by episodes of mania and depression (or
symptoms of both at once, known as mixed features). This prospective, observational study
will examine effectiveness, functioning and... expand
Bipolar I disorder (BP-I) is a common, chronic, and disabling mental illness with significant morbidity and mortality defined by episodes of mania and depression (or symptoms of both at once, known as mixed features). This prospective, observational study will examine effectiveness, functioning and quality of life outcomes in adult patients with BP-I experiencing a major depressive episode (with or without mixed features) requiring treatment and initiating treatment with cariprazine. It will examine outcomes of cariprazine treatment in a real-world setting in patients with BP-I commonly seen in clinical practices. Cariprazine (Vraylar) is a medication indicated in the United States and Canada to treat adult patients experiencing manic, mixed or depressive episodes associated with BP-I. This study plans to enroll approximately 170 adult patients with BP-I from the United States and Canada. Cariprazine should be prescribed by the physician under the usual and customary practice of physician prescription. The decision to initiate treatment with cariprazine should be made prior to, and independently from, the patient's decision to participate in the study. Participants will receive cariprazine as prescribed by their physician. Observational data will be collected during visits which should align to routine standard of care for a duration of up to 24 weeks. Type: Observational Start Date: Apr 2024 |
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to...
Janssen Research & Development, LLC
Depressive Disorder, Major
The purpose of this study is to assess the socio-demographic, disease-related and
treatment-related characteristics, and the standard of care (SOC) treatment patterns of
participants with major depressive disorder (MDD) with anhedonia with inadequate response
to their current antidepressant treatments... expand
The purpose of this study is to assess the socio-demographic, disease-related and treatment-related characteristics, and the standard of care (SOC) treatment patterns of participants with major depressive disorder (MDD) with anhedonia with inadequate response to their current antidepressant treatments and treated according to the standard of care treatment. Type: Observational Start Date: Apr 2023 |
Preventing the Development of Chronic Pain: Treating PTSD at Acute Pain Onset
Rush University Medical Center
PTSD
Chronic Pain
Although most people recover from acute pain (such as pain caused by injury, surgery,
repetitive motion, or unknown causes), many people do not fully recover and will
experience chronic pain. Untreated posttraumatic stress disorder (PTSD) appears to be a
key risk factor for the transition from acute... expand
Although most people recover from acute pain (such as pain caused by injury, surgery, repetitive motion, or unknown causes), many people do not fully recover and will experience chronic pain. Untreated posttraumatic stress disorder (PTSD) appears to be a key risk factor for the transition from acute pain to chronic pain. However, few published studies have addressed the issue of preventing the transition from acute to chronic pain via PTSD reduction. This project will aim to test whether trauma-related PTSD symptoms can be reduced using either Stellate Ganglion Block (SGB) treatment or Cognitive Processing Therapy (CPT), and whether reducing PTSD symptoms can prevent the transition from non-injury based acute pain to chronic pain. Type: Interventional Start Date: Sep 2023 |
Digital Single Session Intervention for Youth Mental Health
Harvard University
Anxiety
Depression
Conduct Disorder
Stress
The aim of this study is to test the effectiveness of a single-session, digital
intervention teaching the principle of practicing the opposite, when administered to
youths on the waitlist for psychotherapy, with usual waitlist procedures as a control
condition. expand
The aim of this study is to test the effectiveness of a single-session, digital intervention teaching the principle of practicing the opposite, when administered to youths on the waitlist for psychotherapy, with usual waitlist procedures as a control condition. Type: Interventional Start Date: Sep 2022 |
How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD
University of Pennsylvania
OCD
Studies show that hormones affect the brain's fear extinction network, which is relevant
for therapy involving exposure and response prevention (EX/RP), a first-line treatment
for obsessive compulsive disorder (OCD). This study will examine the effect of delivering
EX/RP to women during different... expand
Studies show that hormones affect the brain's fear extinction network, which is relevant for therapy involving exposure and response prevention (EX/RP), a first-line treatment for obsessive compulsive disorder (OCD). This study will examine the effect of delivering EX/RP to women during different phases in their menstrual cycle to determine the effects of hormones on the fear extinction network and on their OCD symptoms. Type: Interventional Start Date: Jun 2022 |
Study to Evaluate Weight Gain As Assessed by Change in BMI Z-score in Pediatric Subjects with Schizophrenia...
Alkermes, Inc.
Schizophrenia
Bipolar I Disorder
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs
olanzapine expand
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine Type: Interventional Start Date: Jun 2022 |
Exercise-based Program for Rehabilitation of Veterans With Severe Mental Illness
VA Office of Research and Development
Schizophrenia
Schizoaffective
Bipolar Disorder 1
This is a hybrid1, effectiveness-implementation study of yoga-based exercises (YE) as an
adjunctive tool for rehabilitation among persons with Severe Mental Illness (SMI). The
two-arm randomized controlled trial will compare the efficacy of YE compared to the
Wellness Lifestyle Program (WLP). Primary... expand
This is a hybrid1, effectiveness-implementation study of yoga-based exercises (YE) as an adjunctive tool for rehabilitation among persons with Severe Mental Illness (SMI). The two-arm randomized controlled trial will compare the efficacy of YE compared to the Wellness Lifestyle Program (WLP). Primary outcomes of the study will be self-report and performance-based measures of community functioning, defined in the investigators study as social, leisure, employment, and life skills functioning in the community. Secondary outcomes will include cognition and physical fitness measures. Type: Interventional Start Date: Oct 2022 |
Using Technology to Optimize Collaborative Care Management of Depression in Urban and Rural Cancer Centers,...
University of Washington
Depression
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
This study compares the effectiveness of technology-enhanced collaborative care
management (t-CoCM) to usual collaborative care management (u-CoCM) in achieving fidelity
to processes of care and reducing depression symptoms in patients currently receiving
cancer treatment. CoCM is a population-based,... expand
This study compares the effectiveness of technology-enhanced collaborative care management (t-CoCM) to usual collaborative care management (u-CoCM) in achieving fidelity to processes of care and reducing depression symptoms in patients currently receiving cancer treatment. CoCM is a population-based, integrated care approach, where care managers, who are clinicians (typically clinical social workers), deliver behavioral treatments, coordinate psychosocial care, monitor outcomes, and adjust treatment with the input of a psychiatric consultant. The use of t-CoCM may improve the treatment of depression and improve patient outcomes and quality of life. Type: Interventional Start Date: Apr 2022 |
Behavioral Activation Teletherapy to Increase Physical Activity
University of Texas Southwestern Medical Center
Depression
Depressive Disorder
Depressive Symptoms
Depressive Episode
This is a pilot study of acceptability, feasibility, and preliminary efficacy of a brief,
10-session Behavioral Activation intervention delivered via teletherapy to increase
physical activity and treat depressive symptoms. expand
This is a pilot study of acceptability, feasibility, and preliminary efficacy of a brief, 10-session Behavioral Activation intervention delivered via teletherapy to increase physical activity and treat depressive symptoms. Type: Interventional Start Date: Aug 2021 |
Mindful Moms Randomized Control Trial
Virginia Commonwealth University
Depression
The purpose of this study is to test whether a program called "Mindful Moms" can be
helpful for specific measures of mood and health in pregnant women with depressive
symptoms, compared to group-based education workshops. expand
The purpose of this study is to test whether a program called "Mindful Moms" can be helpful for specific measures of mood and health in pregnant women with depressive symptoms, compared to group-based education workshops. Type: Interventional Start Date: Oct 2021 |
Attentional Biases, Reward Sensitivity, and Cognitive Control in Adults with Bipolar Disorder
University Hospitals Cleveland Medical Center
Bipolar Disorder
The purpose of this study is to use eye-tracking technology to study attentional biases,
reward sensitivity, and cognitive control in adult patients with bipolar disorder with or
without anxiety and/or substance use disorder comorbidity. expand
The purpose of this study is to use eye-tracking technology to study attentional biases, reward sensitivity, and cognitive control in adult patients with bipolar disorder with or without anxiety and/or substance use disorder comorbidity. Type: Observational Start Date: Mar 2019 |
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
National Institute of Mental Health (NIMH)
Mood Disorders
Anxiety Disorders
This study is intended to help develop new MRI imaging techniques for studying mood and
anxiety disorders. Researchers believe that depression and anxiety disorders may cause
structural and functional changes in the brain. This study will optimize the way MRI
scans are collected to look at brain structure... expand
This study is intended to help develop new MRI imaging techniques for studying mood and anxiety disorders. Researchers believe that depression and anxiety disorders may cause structural and functional changes in the brain. This study will optimize the way MRI scans are collected to look at brain structure and examine how the brain behaves while subjects perform particular tasks. Healthy volunteers and individuals with major depressive disorder may be eligible for this study. Participants undergo magnetic resonance imaging (MRI) and neuropsychological testing. : Individuals will be asked to participate in an MRI study on one of several scanners. The scanner used will measure blood flow in the brain, concentrations of certain chemicals in the brain, or magnetic properties of the brain. The scan may involve They watching a screen presenting images or doing a task in which they respond to pictures or sounds. Participants may be asked to return for additional scans. The study also involves neuropsychological tests, which assess cognitive performance. Often, people with mood disorders have subtle changes in performance on these tests that allow researchers to pinpoint where brain abnormalities occur. Before the tests can be used in patients, they must be validated by using healthy subjects. These tests are presented either orally, in written form, or on a computer. Type: Observational Start Date: Dec 2006 |
Concurrent fMRI-guided rTMS and Cognitive Therapy for the Treatment of Major Depressive Episodes
National Institute of Mental Health (NIMH)
Major Depressive Disorder
Background:
Repetitive transcranial magnetic stimulation (rTMS) is a treatment for depression. It
stimulates the brain. Researchers want to see if using magnetic resonance imaging (MRI)
scans helps locate the best area for rTMS in each person. They also want to find other
ways to make it more effective.
Objective:
To... expand
Background: Repetitive transcranial magnetic stimulation (rTMS) is a treatment for depression. It stimulates the brain. Researchers want to see if using magnetic resonance imaging (MRI) scans helps locate the best area for rTMS in each person. They also want to find other ways to make it more effective. Objective: To study the effects of combining MRI- guided transcranial magnetic stimulation (TMS) and talk therapy on the brain in people with depression. Eligibility: Adults ages 18-75 with a major depressive disorder and current depression. If taking an antidepressant, should have been doing so for at least 4 weeks. Design: Participants will be screened with medical and psychiatric history, psychiatric evaluation, physical exam, and blood and urine tests. Phase 1 is 1-4 visits in 1 week. Participants will have: - Brain MRI. Participants will lie on a table in a scanner. - Questions about their medical history and psychology symptoms - Tests of mood and thinking - Tests of brain activity. Participants may do tasks during these tests: - A cone with magnetic detectors is put on the head. - A cap with electrodes is put on the scalp. - TMS. A brief electrical current passes through a wire coil on the scalp. - A metal disk will be placed on the arm. A nerve will be stimulated with a small electrical shock. Phase 2 is about 6 to 7 weeks. - There will be 30 daily sessions of combined therapy and repetitive TMS (rTMS) for 6 weeks. - Participants will receive rTMS and another therapy by computer. - For rTMS, repeated pulses will pass through the coil. - This is followed by up to 3 additional visits, when: - Participants will repeat Phase 1 tests - Participants will rate their depression symptoms. Phase 3 is 3 visits over 3 months. Participants will rate their depression symptoms and repeat some of the previous questionnaires and tests of mood and thinking. Type: Interventional Start Date: May 2018 |
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
Jina Pharmaceuticals Inc.
Bipolar 1 Disorder
Bipolar disorder (BPD) is a chronic debilitating illness characterized by drastic swings
in mood, energy and functional ability that affects the adult population. Endoxifen is an
active metabolite of the marketed drug Tamoxifen and the present study aims to evaluate
the efficacy and safety of 8 mg... expand
Bipolar disorder (BPD) is a chronic debilitating illness characterized by drastic swings in mood, energy and functional ability that affects the adult population. Endoxifen is an active metabolite of the marketed drug Tamoxifen and the present study aims to evaluate the efficacy and safety of 8 mg endoxifen in the Bipolar I disorder patient population compared to a placebo arm. Endoxifen will be compared to a placebo to demonstrate that the test product is active and to establish that the study is sufficiently sensitive to detect differences between the investigational products. Thus, Endoxifen will be compared to placebo to demonstrate that the test product is safe and active. Type: Interventional Start Date: Mar 2024 |
A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With...
Sirtsei Pharmaceuticals, Inc.
Major Depressive Disorder
Depression
Healthy
The main goal of this clinical trial is to learn if the active study drug (code name:
SP-624) has any effect on the electrical activity of the brain in adult healthy
volunteers and in adults with major depression. Another goal of the study is to learn if
SP-624 improves memory and learning in adults... expand
The main goal of this clinical trial is to learn if the active study drug (code name: SP-624) has any effect on the electrical activity of the brain in adult healthy volunteers and in adults with major depression. Another goal of the study is to learn if SP-624 improves memory and learning in adults with major depression. The study will also provide additional information on the safety of SP-624 and how well it is tolerated in adult healthy volunteers and adults with major depression. Researchers will compare SP-624 to a placebo (a look-alike substance that contains no drug) to see if SP-624 has any effect on study tests. Study participants will: Take capsules of study drug (SP-624 or a placebo) once daily for 2 weeks; visit the clinic at Screening, Day 1 (first dose of study drug), and Day 15 (last dose of study drug) for checkups and tests; and have phone call check-ups on Day 7 and about 1 week after the last dose of study drug. Type: Interventional Start Date: Aug 2024 |
New Investigational Stimulation Protocol for Treatment of Major Depression Disorder (MDD)
Brainsway
Major Depressive Disorder
The BrainsWay Deep Transcranial Magnetic Stimulation (Depp TMS) device is intended for
the treatment of depressive episodes in patients suffering from Major Depressive Disorder
(MDD). The device technology is based on the application of deep brain TMS by means of
repetitive pulse trains at a determined... expand
The BrainsWay Deep Transcranial Magnetic Stimulation (Depp TMS) device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep brain TMS by means of repetitive pulse trains at a determined frequency. The purpose of the current study is to evaluate the safety and effectiveness of a new investigational stimulation protocol delivered with the BrainsWay Deep TMS device, for the treatment of MDD, demonstrating that it is non-inferior to the current standard-of-care stimulation protocol, in a randomized, controlled study. Type: Interventional Start Date: Apr 2024 |
Cognitive Behavioral and Faith Fellowship to Improve Thy Health
University of Wisconsin, Madison
Depression
Investigators will examine the efficacy of a faith-based depression intervention, in
reducing symptoms of depression among African American adults in Wisconsin. Twelve church
groups, each with 10 people (N=120) will be invited to participate. This intervention
will be the first evidence-based, faith-based... expand
Investigators will examine the efficacy of a faith-based depression intervention, in reducing symptoms of depression among African American adults in Wisconsin. Twelve church groups, each with 10 people (N=120) will be invited to participate. This intervention will be the first evidence-based, faith-based intervention designed for African Americans if validated. Type: Interventional Start Date: Oct 2024 |
Tracking Brain Biomarkers and Renormalization Associated With Antidepressant Transcranial Magnetic Stimulation...
Medical University of South Carolina
Major Depressive Disorder
This study will attempt to use magnetic resonance imaging (MRI) to take a picture of the
brain to learn about changes that occur in the brain during Transcranial Magnetic
Stimulation (TMS) in people receiving this treatment for depression. expand
This study will attempt to use magnetic resonance imaging (MRI) to take a picture of the brain to learn about changes that occur in the brain during Transcranial Magnetic Stimulation (TMS) in people receiving this treatment for depression. Type: Observational Start Date: Apr 2023 |
Transcranial Magnetic Stimulation for MCI
Medical University of South Carolina
Mild Cognitive Impairment
Depression
The goal of this phase II study is to establish the dose-response curves of a safe and
clinically feasible non-invasive brain stimulation technique (accelerated Transcranial
Magnetic Stimulation (TMS)) to improve both depression and cognitive function in Mild
Cognitive Impairment (MCI) patients with... expand
The goal of this phase II study is to establish the dose-response curves of a safe and clinically feasible non-invasive brain stimulation technique (accelerated Transcranial Magnetic Stimulation (TMS)) to improve both depression and cognitive function in Mild Cognitive Impairment (MCI) patients with comorbid depression. It is known that TMS can effectively treat depression. Identifying the right dose of accelerated TMS in MCI patients is necessary prior to designing subsequent trials to determine efficacy. These results will inform future clinical trials of accelerated TMS for MCI, with the long-term goal of developing an efficacious treatment to prevent dementia. Type: Interventional Start Date: Jun 2024 |
Novel Mental Health Therapies to Improve Military Readiness
David Moss
Anxiety
Alpha Stim
Cranial Electrotherapy Stimulation
Cognitive Behavioral Therapy
Heart Rate Variability
To evaluate the efficacy of CES as a therapy to treat and mitigate symptoms of
generalized anxiety in DoD beneficiaries in a prospective clinical trial and compare this
to sham (placebo) CES. expand
To evaluate the efficacy of CES as a therapy to treat and mitigate symptoms of generalized anxiety in DoD beneficiaries in a prospective clinical trial and compare this to sham (placebo) CES. Type: Interventional Start Date: Jan 2024 |
- Previous
- Next